THE DEAL, AT A GLANCE
2/4 explanations supportedCircle Pharma
Circle Pharma
Circle Pharma develops macrocycle cancer medicines aimed at targets conventional drugs cannot reach.
01What it doesCircle Pharma develops macrocycle cancer medicines aimed at targets conventional drugs cannot reach.Source-grounded · automated review · Explore ↗
Checked 2026-09-16 · Review due 2026-09-23
Read supporting source ↗Our proprietary MXMO™ platform was…
02Who is involvedEvidence still neededOpen review status ↗
The draft correctly does not name investors; document 0 contains no investors, previous-round investors, lenders, arrangers, or financing participants.
03What happenedEvidence still neededOpen review status ↗
The draft correctly rejects the transaction claim; document 0 does not establish a Series E financing event, announcement date, amount, currency, valuation, or round details.
04Why it mattersIts medicines could make cancer therapy more comfortable with fewer side effects.Interpretation · Explore ↗
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Circle Pharma · Financing Record
Explore source-linked visual explanations for Circle Pharma. Unsupported claims are withheld while source review continues.
Record 12423 · Recorded date: 2026-09-16
Explore company records →